top of page
  • White LinkedIn Icon
  • White Facebook Icon

About

For over 25 years KGI Life Science Advisors has focused on cross-border life science transactions between the US/Europe and Japan/Asia Pacific

Overview

KGI Life Science Advisors is a US-based boutique consulting and transaction advisory practice focused on cross-border strategic life science transactions between the US/Europe and Japan/Asia Pacific. However, our experience and reach are global covering more than 40 countries in all geographic regions. On average our principals have over 25 years of business development, licensing and transaction experience.

Deal Connections

We are deal connectors with an ever growing network of over 3,000 C-level contacts and decision-makers in more than 2,000 life science organizations worldwide spanning all industry sectors and therapeutic areas. 

Deal Execution

We are deal closers with a deal sheet that includes 30 transactions valued at more than $1.6 billion, not including transactions currently under negotiation.  While our "sweet spot" is emerging and small/mid-cap companies, we also work with large biopharma companies and leading service providers.

 

Preferred Provider Network

We understand that the business of life science is closely intertwined with R&D, clinical, regulatory, IP, manufacturing and other functions critical to success.  Unfortunately, we cannot do them all.  Therefore, we have established a network of preferred provider relationships with partners who can offer services in these areas to our clients. We have selected preferred providers based on our own positive experience of working with them as former clients.

Earth.jpg

Life Science Industry Coverage

We have worked in all therapeutic sectors and stages of the life science industry and offer consulting, business development and transaction advisory services in the following areas:

  • Human and Animal Health

  • Drug Discovery - Computational, Simulation and AI

  • Biopharmaceuticals

  • Autologous and Allogeneic Cell-Based Therapies

  • MSC Cell-Free Secretome and Exosome-Based Therapies

  • Vaccines

  • Dental and Oral Health

  • Medical Devices, Medical Technologies and IT

  • Diagnostics and Reagents

  • Consumer Health, Beauty and Wellness 

  • Contract Research (CROs)

  • Contract Development and Manufacturing (CDMOs)​

  • Research KOL and Clinical Centers of Excellence (COE)

  • Venture Capital, Private Equity and Non-Dilutive Funding 

bottom of page